BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin SP, Fako V, Dang H, Dominguez DA, Khatib S, Ma L, Wang H, Zheng W, Wang XW. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:99. [PMID: 32487192 DOI: 10.1186/s13046-020-01605-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Kapuy O, Makk-Merczel K, Szarka A. Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine. Biomolecules 2021;11:652. [PMID: 33925206 DOI: 10.3390/biom11050652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Weiss CR, Nezami N. One Step Closer to Precision Medicine for Transarterial Therapy of HCC. Radiology 2020;297:235-6. [PMID: 32804050 DOI: 10.1148/radiol.2020202843] [Reference Citation Analysis]
3 Chen X, Chen S, Yu D. Protein kinase function of pyruvate kinase M2 and cancer. Cancer Cell Int 2020;20:523. [PMID: 33292198 DOI: 10.1186/s12935-020-01612-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mirzaei S, Hushmandi K, Zabolian A, Saleki H, Torabi SMR, Ranjbar A, SeyedSaleh S, Sharifzadeh SO, Khan H, Ashrafizadeh M, Zarrabi A, Ahn KS. Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies. Molecules 2021;26:2382. [PMID: 33921908 DOI: 10.3390/molecules26082382] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
5 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
6 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Reference Citation Analysis]
7 Pan Y, Hu GY, Jiang S, Xia SJ, Maher H, Lin ZJ, Mao QJ, Zhao J, Cai LX, Xu YH, Xu JJ, Cai XJ. Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma. Front Oncol 2021;11:637971. [PMID: 34094917 DOI: 10.3389/fonc.2021.637971] [Reference Citation Analysis]
8 Patel S, Globisch C, Pulugu P, Kumar P, Jain A, Shard A. Novel imidazopyrimidines-based molecules induce tetramerization of tumor pyruvate kinase M2 and exhibit potent antiproliferative profile. Eur J Pharm Sci 2021;:106112. [PMID: 34971746 DOI: 10.1016/j.ejps.2021.106112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
11 Wang L, Li B, Bo X, Yi X, Xiao X, Zheng Q. Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway. Exp Mol Med 2022;54:848-60. [PMID: 35764883 DOI: 10.1038/s12276-022-00767-3] [Reference Citation Analysis]
12 Xia H, Huang Z, Wang Z, Liu S, Zhao X, You J, Xu Y, Yam JWP, Cui Y. Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma. Front Oncol 2022;12:953668. [DOI: 10.3389/fonc.2022.953668] [Reference Citation Analysis]
13 Chen M, Li J, Shu G, Shen L, Qiao E, Zhang N, Fang S, Chen X, Zhao Z, Tu J, Song J, Du Y, Ji J. Homogenous multifunctional microspheres induce ferroptosis to promote the anti-hepatocarcinoma effect of chemoembolization. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01385-x] [Reference Citation Analysis]
14 Wu H, Du J, Li C, Li H, Guo H, Li Z. Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis. Int J Mol Sci 2022;23:3544. [PMID: 35408903 DOI: 10.3390/ijms23073544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of Early TACE Refractoriness on Survival in Patients with Hepatocellular Carcinoma: A Real-World Study. J Hepatocell Carcinoma 2022;9:621-31. [PMID: 35903756 DOI: 10.2147/JHC.S373112] [Reference Citation Analysis]
16 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yu JH, Ma S. Organoids as research models for hepatocellular carcinoma. Exp Cell Res 2021;411:112987. [PMID: 34942189 DOI: 10.1016/j.yexcr.2021.112987] [Reference Citation Analysis]
18 Liu Y, Wang X, Zeng X, Wu Y, Liu X, Tan J, Li X. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation. Open Med (Wars) 2022;17:1183-202. [PMID: 35859792 DOI: 10.1515/med-2022-0510] [Reference Citation Analysis]
19 El-Sahli S, Wang L. Cancer Stem Cell-Associated Pathways in the Metabolic Reprogramming of Breast Cancer. Int J Mol Sci 2020;21:E9125. [PMID: 33266219 DOI: 10.3390/ijms21239125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zheng J, Liu J, Zhu T, Liu C, Gao Y, Dai W, Zhuo W, Mao X, He B, Liu Z. Effects of Glycolysis-Related Genes on Prognosis and the Tumor Microenvironment of Hepatocellular Carcinoma. Front Pharmacol 2022;13:895608. [DOI: 10.3389/fphar.2022.895608] [Reference Citation Analysis]
21 Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, Zhao H, Chen L, Ming T, Meng X, Xu H. Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches. Phytomedicine 2022;94:153805. [PMID: 34749177 DOI: 10.1016/j.phymed.2021.153805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
22 Wang R, Fu Y, Yao M, Cui X, Zhao Y, Lu X, Li Y, Lin Y, He S. The HN1/HMGB1 axis promotes the proliferation and metastasis of hepatocellular carcinoma and attenuates the chemosensitivity to oxaliplatin. FEBS J 2022. [PMID: 35596723 DOI: 10.1111/febs.16531] [Reference Citation Analysis]
23 Marcucci F, Rumio C. Glycolysis-induced drug resistance in tumors-A response to danger signals? Neoplasia 2021;23:234-45. [PMID: 33418276 DOI: 10.1016/j.neo.2020.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Zhang W, Guo X, Ren J, Chen Y, Wang J, Gao A. GCN5-mediated PKM2 acetylation participates in benzene-induced hematotoxicity through regulating glycolysis and inflammation via p-Stat3/IL17A axis. Environ Pollut 2021;295:118708. [PMID: 34929209 DOI: 10.1016/j.envpol.2021.118708] [Reference Citation Analysis]